Assignee
VIRACTA THERAPEUTICS INC
US·3 granted patents·14 pending applications·6 citations·filing 2017–2025
Top patents by PatentIndex Score
17 records- 0191US10857152B2Methods and compositions for treating viral or virally-induced conditionsVIRACTA THERAPEUTICS INC·Filed 2018·Granted Dec 8, 2020·3 cites·11 claims
- 0285US10953011B2Methods of treating virally associated cancers with histone deacetylase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2020·Granted Mar 23, 2021·3 cites·25 claims
- 0384US2024246988A1Bruton's tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0484US2024294524A1Heterocyclic compounds useful as pdk1 inhibitorsVIRACTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0583US2024417389A1Pyrimidinyl tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0678US2023046457A1Bruton's tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0777US2023113598A1Heterocyclic compounds useful as pdk1 inhibitorsVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0877US2023174511A1Pyrimidinyl tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0976US2024342172A1Methods and compositions for treating viral or virally-induced conditionsVIRACTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1075US2026007676A1Hdac inhibitors for use with nk cell based therapiesVIRACTA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1173US2024207258A1Heterocyclic pdk1 inhibitors for use to treat cancerVIRACTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1270US2022133718A1Pharmaceutical formulations, processes for preparation, and methods of useVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1368US2023099829A1Heterocyclic pdk1 inhibitors for use to treat cancerVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1459US12427152B2HDAC inhibitors for use with NK cell based therapiesVIRACTA THERAPEUTICS INC·Filed 2017·Granted Sep 30, 2025·0 cites·7 claims
- 1558US2026083848A1Combination of car t-cell therapy with btk inhibitors and methods of use thereofVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1644US2024058347A1Dosages for hdac treatment with reduced side effectsVIRACTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1734US2020368280A1Epigenetic modifiers for use in cellular immunotherapyVIRACTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when VIRACTA THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →